GSK's Mekinist recommended in Europe as Novartis looks on

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended GlaxoSmithKline's Mekinist (trametinib) as a single agent treatment for melanoma with a BRAF V600 mutation. Mekinist is part of GSK's $16bn sale of its oncology division to Novartis through the mega asset swap deal announced earlier this week (scripintelligence.com, 22 April 2014).

Novartis is paying GSK $14.5bn up front and up to $1.5bn contingent on the results of the Phase III COMBI-d...

More from Anticancer

More from Therapy Areas